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In the present review, an association between cancer and the activity of the non-LTR retroelements L1, Alu, and SVA, as well 
as endogenous retroviruses, in the human genome, is analyzed. Data suggesting that transposons have been involved in embryo-
genesis and malignization processes, are presented. Events that lead to the activation of mobile elements in mammalian somatic 
cells, as well as the use of mobile elements in genetic screening and cancer gene therapy, are reviewed.
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MOBILE ELEMENTS
Mobile elements (ME), also called junk DNA 
or transposable elements, are present in the genome 
of all known eukaryotes. In mammals, MEs make 
up at least 45% of the genome [1, 2], while their con-
tent in other organisms varies from some 2.7% in the 
fish Fugu rubripes [3] to above 90% in some plants 
[4]. Many authors define MEs as nucleotide sequenc-
es capable of changing their position in the host ge-
nome [5–7]. Meanwhile, some authors compliment 
this definition by pointing out the MEs’ ability to change 
also their copy numbers, i.e. to replicate indepen-
dently from the host genome [8, 9]. Besides, MEs are 
sometimes referred to as parasitic nucleotide se-
quences which replicate independently from the host 
genome and can not be purged of by sexual reproduc-
tion [10]. All these definitions, complementing each 
other, are by no means thorough though, as a versatile 
definition of MEs would require an exhaustive survey. 
To summarize, it’s also worth accenting that MEs are 
inherent to the genomes of all organisms, including 
humans, just like mitochondrial and plastid genomes 
[11]. Appreciating the role of MEs in their host ge-
nomes, they have been portrayed during last years as 
“genome architects” [12], “genome’s treasure” [13], 
“drivers of evolution” [6, 8], etc. On the one hand, this 
reflects the understanding of the important role played 
by MEs. On the other, however, we are yet far from 
thorough apprehension of their function.
MEs are believed to influence the host genome 
in several ways. Their active transposition is one of the 
causative factors of mutation processes [14–16]. MEs’ 
nucleotide sequences can also serve as promoters, 
enhancers, silencers, as well as sites of epigenetic 
modifications and alternative splicing, in the host 
genome [6, 17, 18]. Following molecular domestica-
tion, MEs may lose their autonomy and become part 
of other host genome’s components [19–24]. Large 
ME numbers in a genome stimulate the formation 
of deletions, duplications, inversions, or transloca-
tions as a result of ectopic recombination [25–27]. 
Therefore, the effect of MEs on the human genome 
is diverse: MEs often take part in important genomic 
functions and provide material for natural selection, 
and failures and errors in their function lead to genome 
damage and disease, including cancer.
The general classification based on transposition 
mechanisms is universal to all eukaryotes [28, 29] 
and divides MEs into two groups: transposons that 
relocate via the “cut and paste” mechanism, and 
retroelements that make use of RNA intermediates 
and reverse transcription. The grouping within these 
classes is also universal to diverse organisms, with 
retroelements classified into two groups (LTR-, for 
long terminal repeats, and non-LTR retroelements) 
and transposons represented by three groups (“roll-
ing circle”, “cut and paste”, and “self-synthesizing” 
transposons). However, more detailed classification, 
on the level of ME families, appears to be host genus-
specific [1, 2, 30], though the exceptions of multi-
genus ME families or families not universal to all the 
genus members do exist. A number of factors have 
been pointed out to explain these exceptions, such 
as horizontal transmission between genera [31], 
or loss of some ME families during speciation within 
a genus [32].
Most of non-LTR retroelement families in the human 
genome are currently inactive, except for three families. 
LINE-1 (long interspersed nuclear elements), or L1, ele-
ments make up near 17% of human genomic DNA, with 
a total of about 500,000 copies [1]. Full-size L1 elements, 
stretching for some 6 kb, have two open reading frames 
encoding proteins required for their transposition and re-
location of non-autonomous elements of the SINE (short 
interspersed nuclear elements) family. L1 have been ac-
tive in the human genome for near 160 million years [1].
The SINE elements are short (100–400 bp). They 
contain a promoter for polymerase III and do not 
encode proteins. The vast majority of known SINE 
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elements are tRNA derivatives. One exception is the 
Alu element. Over a million copies of this element 
comprise some 11% of the human genome [1]. This 
element is specific to primates and has been coloni-
zing primate genomes since 65 million years ago [16].
Another group of non-autonomous retroelements 
that are active in humans and use the L1 elements’ 
machinery (just like the SINEs) for transposition and 
are specific to hominids is SVA (SINE-VNTR-Alu; VNTR 
for variable number of tandem repeats) elements [33], 
which have been colonizing the human genome since 
relatively recently (less then 25 million years) and cur-
rently total near 3,000 copies [34].
NON-LTR ELEMENTS IN TUMOR 
DEVELOPMENT
A link between the transposition of mobile ele-
ments in the human genome and some pathologies, 
including cancer, was noted a many years ago [28, 
35]. For instance, in the 1980s L1 retroelement in-
sertion into the human protooncogene c-myc was 
found in human breast cancinoma cells [35]. Another 
example of somatic insertions of this mobile element 
is its integration into the tumor-suppressing gene apc 
(adenomatous polyposis coli), which has been found 
in colon cancer patients [36]. Insertions of the Alu 
 element into the intron of the NF-1 (neurofibromatosis 
type I) gene lead to a deletion and a reading frame shift 
in the downstream exon during splicing, which might 
be associated with neurofibromatosis [37].
ME insertions are not evenly distributed in the 
genome. There are certain characteristic insertion 
sites where ME integration is most likely. Thus, the 
above-mentioned apc gene can be target for L1 and 
Alu element insertions [14]. In general, combined L1, 
Alu, and SVA insertions only account for about 0.27% 
(118 out of 44,000) of all known human mutations [33], 
so their contribution to mutation processes appears 
to be rather marginal.
Meanwhile, there are other types of cancer which 
are linked to MEs indirectly. For example, mobile ele-
ments (Alu) may play a role in chronic myeloid leu-
kemia, which develops as a result of a translocation 
between the human chromosomes 9 and 22, as the 
chromosome breakpoints producing this chromosome 
aberration contain nucleotide sequences of this ele-
ment. Therefore, essentially this chromosome aber-
ration results from ectopic recombination between 
identical sequences of different Alu elements [38]. 
Similarly, an internal tandem duplication of part of the 
mll (myeloid/lymphoid or mixed-lineage leukemia) 
gene, which results from ectopic recombination be-
tween those very Alu elements, may trigger a cascade 
of events which is frequently associated with acute 
myeloid leukemia [39]. Recombination between Alu 
elements which causes a translocation involving the 
TRE (USP6, ubiquitin-specific protease 6 (Tre-2 onco-
gene)) oncogene has been shown to play an important 
role in Ewing sarcoma development [40]. Being far 
from complete, this list is still sufficient to illustrate 
that ME-linked rearrangements in the human genome 
may be associated with cancers of various etiology.
THE ROLE OF MEs IN GENOME 
FUNCTIONING
Although the above-mentioned facts suggest the 
on involvement of non-LTR mobile elements in tu-
morigenesis, the question of specific processes that 
are responsible for triggering ME-linked genome 
disturbances in the human genome remains open. 
As it becomes evident from recent studies, there 
are several ways of ME activation, both in germ and 
somatic cells. For example, L1 elements are known 
to actively transpose during early embryogenesis, 
which is believed to be triggered by total genome 
demethylation, or the so-called epigenetic reprogram-
ming, which has been shown in muzine primordial cells 
between the E11.5 and E13.5 early embryo stages 
[41]. As DNA methylation is known to repress various 
nucleotide sequences, including L1 elements, de-
methylation may cause ME activation with the ensuing 
insertion events. Kano et al. [42] have demonstrated 
that mRNA from L1 elements transcribed in the pa-
rental organism can be passed on through oocytes 
or sperm cells to progeny where reverse transcription 
ensures further insertions of the element’s copies 
into the genome of the developing organism during 
the pre-implantation stage, which leads to somatic 
mosaicism. It seems, therefore, that at least two ways 
of L1 activation exist during early stages of mammal 
development [43]. It can be envisioned that during this 
early developmental period, as the embryonal cells 
divide, the retroelement activity aftereffects are tested 
for compatibility with life. In this way, insertions that 
survive in somatic tissues create phenotypic diversity 
without changes in the genome of generative cells. 
Human neural progenitor cells, in which L1 element 
activity in embryo brain produces somatic mosaicism 
[44, 45], are a bright example of this type of somatic 
retrotranspositions. Such a mosaicism could poten-
tially affect neuron formation and, thus, create indi-
vidual characteristics and phenotypic diversity of the 
brain [41]. Therefore, ME activation is rather common 
during embryogenesis, and retroelement insertions, 
including those associated with cancer development, 
may be considered as the cost of phenotypic diversity 
formation.
There is evidence suggesting that MEs have been 
important in mammal evolution. In particular, the origin 
of mammals as a class, specifically the emergence 
of the genes controlling placenta development, was 
catered by the domestication of mobile elements [46]. 
At least 50 of the human genes are known to originate 
from MEs, predominantly from DNA transposons [1]. 
Currently active transposons are not known from 
the human genome, however, as yet mentioned, the 
human genome contains genes that were formed 
as a result of transposon domestication [19]. For 
instance, the genes responsible for somatic diversity 
formation in the immune system and playing a crucial 
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role in V(D)J recombination during lymphocyte devel-
opment (recombination-activating genes RAG1 and 
RAG2), originate from the nucleotide sequences of the 
ancient Transib superfamily of transposons [47, 48]. 
The RAG genes still even retain their ability to relocate 
their nucleotide sequences during V(D)J recombina-
tion in the genome of lymphocytes [49]. V(D)J recom-
bination events are biochemically similar to the trans-
position of the Hermes family of transposons, such 
as hobo, Activator, and Tam3, which relocate via the 
“cut-and-paste” mechanism [50]. In fact, a nucleotide 
sequence fragment cut out during V(D)J recombina-
tion resembles transposon DNA, being though, un-
like the latter, circularized. Fragments cut out by the 
RAG proteins usually degrade. However, sometimes 
the proteins can reinsert these fragments into other 
sites in the genome [51–53]. Such insertions have 
been demonstrated, for example, in the hprt (hypo-
xanthine-guanine phosphoribosyl transferase) locus 
in human T cells in vivo [54]. In human cell culture, the 
frequency of such insertions, according to different 
estimates, may be 1 per 13,000–50,000 recombination 
events. If this rate also holds for human lymphocytes, 
this means 10,000 insertions in a human organism 
each day [55]. Of course, this rate may well turn out 
to be an overestimation which cannot be directly ex-
trapolated from cell culture to an organism. However 
a link between these events and B- and T-cell ma-
lignization in the human organism can be tentatively 
presumed.
Although specific health consequences of RAG-
mediated insertions in blood lymphocytes have not 
been reported so far, a link between V(D)J recombina-
tion and the onset of cancer associated with chromo-
some rearrangements induced by the recombination 
has been demonstrated [56, 57]. RAG proteins may 
induce double-strand breaks (DSB) in sites similar 
in their structure to signal sequences for V(D)J re-
combination. Such DSBs in DNA are potential players 
in recombination of the genes or receptors of mature 
T and B cells. This, in turn, entails deviations in the 
expression of such protooncogenes as LMO2 (LIM 
domain only 2 (rhombotin-like 1)) and BCL2 (B-cell 
lymphoma 2).
However, the list of cancer-linked chromosome 
rearrangements extends beyond those caused by de-
fects in the functioning of the V(D)J recombination 
genes. Oncogenic chromosome rearrangements can 
be formed at fragile chromosome sites due to imperfect 
functioning of the NHEJ (non-homologous end joining) 
and homologous recombination reparation systems. 
The breakpoints during oncogenic translocations, 
deletions, and other chromosome rearrangements 
often localize in/near the nucleotide sequences of Alu 
elements [26]. Such events are referred to as cancer-
linked Alu-mediated events of non-allelic homologous 
recombination (NAHR). Among such rearrangements, 
deletions are the most common, duplications occur 
less frequently, and translocations are the rarest [9]. 
The existence of ectopic recombination between Alu 
sequences leading to DNA deletions in germ cells 
is beyond doubt today, and still such events are rare 
in somatic cells [58] (see also the examples of acute 
myeloid leukemia and Ewing sarcoma above). The 
presence of an Alu sequence itself has been found 
to have little effect. It is the type of this sequence, 
provided that a recombination-initiating DSB forms 
within it, that determines what scenario will NHEJ 
or SSA (single strand annealing) reparation follow [59, 
60]. And this, eventually, may determine the final type 
and complexity of the rearrangement.
ME ACTIVITY AND ENVIRONMENTAL 
FACTORS
The activity of L1 and L1-dependent MEs may 
be affected by environmental factors, which can 
activate the elements. Several chemicals containing 
mercury (HgS), cadmium (CdS), and nickel (NiO) have 
been found to elevate the activity of L1 three times 
in human cell culture [61]. Meanwhile nickel chloride, 
which increases L1 activity 2.5 times, has no direct ef-
fect on the sequence of the element or its proteins, but 
instead inhibits DNA reparation systems, which even-
tually leads to L1 transpositions [62]. In general, active 
ME transposition in various living organisms is known 
to be induced by a number of environmental factors, 
like heat shock, viral infection, poisons, detergents, 
other chemicals, energy metabolism abnormalities, 
etc [63]. ME transcription and transposition rates 
have also been found to increase under γ irradiation 
[64, 65]. Indirectly, through ME activation, therefore, 
all these agents, as well as those yet not studied 
for ME activity effects, could potentially contribute 
to human carcinogenesis. This effect of external 
factors on ME-mediated carcinogenesis is further 
supported by the geographic patterns found in these 
events. For example, a number of studies link the 
rates of BRCA2 gene expression specific to Portugal 
population to Alu activity [66, 67].
ENDOGENOUS RETROVIRUSES 
AND CARCINOGENESIS
So far we described ME effects on carcinogenesis 
caused by transposons and non-LTR retroelements 
in humans. Another group of mobile elements known 
to be linked to cancer is human endogenous retrovi-
ruses (HERVs). These belong to LTR retroelements 
and make up near 8.3% of the human genome, with 
a total of 0.3x106 copies. This group of elements is the 
most diverse one in the human genome and comprises 
as much as 6 superfamilies, three of which being cur-
rently inactive [68]. The structure of these elements 
incorporates modified main retroviral structural com-
ponents in the order 5’-gag-pro-pol-env-3’. The gag 
gene encodes the matrix and capsid proteins, pro — 
a protease, pol — a reverse transcriptase, the RNAse 
H and an integrase, and env — the envelop proteins. 
Alongside with these genes, endogenous retroviruses 
may have other, non-structural genes [69]. Endog-
enous retroviruses originate from ancient infections, 
however now they have lost their ability to form self-
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contained infectious entities. Still, there is evidence 
suggesting that at times the infectious property may 
form spontaneously during cell division [70].
The HTLV-1 (human T cell leukemia virus) retrovi-
rus is known to cause monoclonal leukemia in 1–2% 
of infected persons, with the latent period sometimes 
reaching up to 50 years. Proteins of this virus can speed 
up cell proliferation by interacting with some genes [71]. 
The retrovirus HTLV-2 is also known to have some carci-
nogenic potential [72]. High titers of the retrovirus XMRV 
(xenotrophic murine leukemia virus) have also been 
detected in patients with prostate carcinoma [73–75].
Data from literature indicate that HERVs are 
responsible for at least 2 types of human patholo-
gies — autoimmunity and cancer. Animal oncogenic 
viruses are believed to be able to transform normal 
cells via three different mechanisms: a) multiplication 
of an endogenous virus which requires a co-infection 
with a wild-type virus to provide the necessary ma-
chinery, b) insertional mutagenesis interrupting proper 
functioning of tumor-suppressing genes, c) regulation 
of the expression of genes controlling cell proliferation 
and some other processes. All these three mecha-
nisms can only be used by viruses capable of being 
transferred horizontally, like MLV (mouse leukemia 
virus), MMTV (mouse mammary tumor virus), FeLV 
(feline leukemia virus), PERVs (porcine endogenous 
retroviruses), KoRV (koala retrovirus) [76, 77]. HERV 
can also influence tumor development indirectly via 
the immunosuppressive function of the Env proteins. 
This property has been reported for these proteins 
in HERV-K, Moloney MLV, and MPMV (Mason-Pfizer 
monkey virus) [78, 79].
Therefore, based on these data, the HERV activity 
can be assumed to serve as a co-factor in a complex 
involved in the multi-step process of tumor develop-
ment in humans.
ME BEHAVIOR IN THE TUMOR CELL 
GENOME
The genomic behavior of MEs in transformed tis-
sues deserves separate examination, as it differs from 
that in normal cells. For instance, the activity of L1 and 
HERV are known to be higher in tumor cells compared 
to normal cells, which might potentially lead to higher 
mutation rates in tumor cells. Rates of recombination 
are also notably higher in tumor cells, which might 
partially explain the high rate of chromosome rear-
rangements in these cells [80, 81]. The activity of MEs 
in somatic and germinal cells are controlled by a num-
ber of repression systems, like post-transcriptional 
silencing via RNA interference and chromatin modifi-
cations [82]. To become activated MEs need to elude 
this control. As chromatin (both DNA and proteins) 
is often hypomethylated in tumor cells, which changes 
its conformation, L1 and HERV promoters may be re-
leased with the ensuing he activation of the elements 
[83]. Also, tumor cells are known to contain signifi-
cantly lower quantities of micro RNAs [84]. Micro RNAs 
are involved in RNA interference, so this repression 
mechanism is quenched in cancerous cells. Interest-
ingly, high titers of HERV-K RNA and high activity of the 
reverse transcriptase have been reported in patients 
with certain forms of lymphomas and breast cancer 
[85]. Transcripts of the gene Np9 of the endogenous 
retrovirus K are found in 50% of cell cultures estab-
lished from germ cell cancers as well as breast cancer 
and leukemia tissues [86]. HERV-K-like viruses have 
been found in human melanomas [87]; iRNA and pro-
teins of these endogenous viruses have been isolated 
from primary melanomas, melanoma metastases, and 
cultured melanoma cells [88]. However, the question 
of the causative nature of this system remains open, 
i.e., whether it’s that increased retrovirus titer that 
causes tissue transformation or vice versa.
Therefore, while MEs may be linked to cancer de-
velopment, they themselves can get activated by the 
cell malignization processes, the latter promoting 
increased mutation and recombination rates in the 
genome of the transformed cells.
TRANSPOSONS AS A MEANS OF GENETIC 
SCREENING 
Insertional mutagenesis is a tool for identifica-
tion of genes involved in different functional cellular 
processes [89]. However, this approach is practi-
cally impossible on humans, except, perhaps, for cell 
cultures. So the most common mammalian models 
are mice and rats, in which insertional mutagenesis 
is a means of genetic screening of cell components 
involved in malignization. In this way, retroviruses are 
used for identification of mouse cancer-associated 
genes [90]. Oncogenic retroviruses are represented 
by two classes: transforming retroviruses invoking 
the development of acute polyclonal tumor during 
2–3 weeks after infection [91] and transforming ret-
roviruses causing non-acute mono- and oligoclonal 
tumor with the latent period up to 12 month. The latter 
integrate into the host cell’s genome via insertions, and 
it’s these retroviruses that are used in genetic screen-
ings for malignization-linked genes in mammals [92]. 
However, the applicability of this approach is limited 
by the insertional predilection of these retroviruses 
to integrate into the genomes of blood and mammary 
cells [93].
DNA transposons, which are active in the ge-
nomes of many invertebrates, are inactive in verte-
brates. These mobile elements have become the 
basis for genetically engineered transposons capable 
of transposing in mammalian tissues [94, 95], which 
has opened a unique perspective for applying such 
synthetic mobile elements in insertional mutagenesis 
to reveal as many mammalian (and human) cancer-
related genes as possible. The Sleeping Beauty (SB) 
transposon of the TC1/mariner family, for instance, 
was constructed based on an inactive element from 
fish optimized to transpose in multi-cellular systems, 
including mouse stem cells [96]. Another transposon, 
PiggyBac (PB), originating from the cabbage looper 
Trichoplusia ni, has recently been constructed with 
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the ability to efficiently transpose in mammal cells 
[97]. Other synthetic transposons have also been 
constructed (like Tol2, Mos1, Frog Prince etc), but 
SB and PB have been found to be the most adequate 
for cancer research [98]. These two transposons dif-
fer in that PB can carry longer DNA fragments, it has 
a weaker tendency to transpose locally, and does not 
leave undesired “footprints” at the sites it cuts off 
from. SB and PB also prefer a little different integra-
tion sites [99].
These approaches have resulted in eliciting over 
20 types of tumors and the identification of new can-
didate cell malignization-associated genes. Therefore, 
the main tumorigenesis-controlling mechanisms can 
be assumed to involve a certain combination of pro-
moters and their genes [100].
TRANSPOSONS AND CANCER GENE 
THERAPY
Gene therapy is being increasingly applied 
in cancer treatment. Classic ways to achieve stable 
expression of alien genes in vertebrates are founded 
on various methods of gene construct delivery in cell 
culture, like transfection [101] by electroporation 
[102], sonoporation [103], needleless injection [104], 
etc. The main problems with these approaches center 
around the low integration efficiency and unstable 
expression of the constructs, which can be explained 
by the injected DNA concatemerization preceding its 
integration into the genome [105]. Another problem 
is that the transgenic cell groups are mosaic. γ retro-
viral and lentiviral vectors have also been used to in-
tegrate foreign DNA into the tumor cell chromosomes 
[106]. The drawbacks of using such vectors stem from 
their profound mutagenic effects [107] and the risk 
of an immune response in patients subjected to this 
type of gene therapy.
Meanwhile, transposons-based techniques avoid 
all these problems and ensure safe and non-toxic 
expression of inserted sequences. For example, the 
SB transposons-based vectors have successfully 
been used to deliver the genes sFlt-1 (soluble vascu-
lar endothelial growth factor receptor) and statin-AE 
(angiostatin-endostatin fusion gene) into the human 
glioblastoma. Such transformation decreased the 
tumor size and increased the proportion of animals 
that survived [108]. Antigen-specific T-cells containing 
receptors to the genes p53 and MART-1, which had 
been constructed using an SB-based vector, demon-
strated stable expression (50% of the cells) and were 
functionally efficient against tumor cells [109]. Today, 
a new generation of “hyperactive” SB-based vectors 
is used, like SB100X [110–112]. A bright example 
of the efficiency of such vectors comes from another 
study in which Kang et al. [113] applied gene-directed 
enzyme-prodrug therapy (GDEPT) using a PB-based 
vector to treat ovarian adenocarcinoma. Based on their 
results, the authors argue that PB is the most efficient 
transposon for stable genomic integration among the 
known mammal systems. Whether or not, there exists 
a kind of “improvement race” among different vector 
systems [114] whereby the systems become more and 
more efficient, and so there is a hope that this race will 
end up in some reliable cancer treatment techniques.
CONCLUSION
Our understanding of the role of MEs in tumori-
genesis has evolved from factors involved in tumor 
development to methods of genetic screening of cell 
components involved in malignization and eventually 
to gene therapy of various forms of cancer. Now, it has 
become evident that the role of MEs in the initiation 
of some tumor types in vertebrates should be con-
sidered as an inevitable consequence of their vast 
genomic involvement in the generation of somatic cell 
diversity. So, like every benefit in nature, the evolution-
ary contributions of MEs to the host genome come 
at a price.
ACKNOWLEDGMENT
Authors thank Andrii Rozhok for help in obtaining 
some papers and English translation.
REFERENCES 
1. Lander ES, Linton LM, Birren B, et al. Initial se-
quencing and analysis of the human genome. Nature 2001; 
409: 860–921.
2. Chinwalla AT, Cook LL, Delehaunty KD, et al. Mouse 
Genome Sequencing Consortium. Initial sequencing and 
comparative analysis of the mouse genome. Nature 2002; 
420: 520–62.
3. Aparicio S, Chapman J, Stupka E, et al. Whole-genome 
shotgun assembly and analysis of the genome of Fugu rubripes. 
Science 2002; 297: 1301–10.
4. Kunze R, Saedler H, Lonning W-E. Plant transposable 
elements. Adv Bot Res 1997; 27: 331–470.
5. Khesin RB. Genome instability. Moscow, Nauka. 
1984: 472 (in Russian).
6. Kazazian HHJr. Mobile elements: drivers of genome 
evolution. Science 2004; 303: 1626–32.
7. Ivics Z. Genome parasites and genome evolution. Ge-
nome Biology 2009; 10: 306 (doi:10.1186/gb-2009-10-4-306)
8. Ivics Z, Izsvak Z. Repetitive elements and genome 
instability. Sem Cancer Biol 2010; 20: 197–9. 
9. Konkel MK, Batzer MA. A mobile threat to genome 
stability: The impact of non-LTR retrotransposons upon the 
human genome. Sem Cancer Biol 2010; 20: 211–21.
10. Abrusan G, Krambeck HJ. Competition may deter-
mine the diversity of transposable elements. Theor Popul Biol 
2006; 70: 364–75.
11. Pidpala OV, Yatsishina AP, Lukash LL. Fragments 
of bacterial IS elements and mobile genetic elements in human 
mtDNA. In: Advances and Problems in Genetics, Selection, 
and Biotechnology: Research series / Ukrainian M.I. Vavilov 
Society of Geneticists and Breeders. — Kyiv: Logos, 2007. — 
V.1. — P. 498–502 (in Ukrainian).
12. Kolotova TYu, Stegnii BT, Kuchma IYu, et al. Mecha-
nisms and control of genome rearrangements in eukaryotes. — 
Kharkiv: Kollegium, 2004: 264 (in Russian).
13. Makalowski W. Genomics. Not junk after all. Science 
2003; 300: 1246–7.
14. Chen JM, Stenson PD, Cooper DN, et al. A systematic 
analysis of LINE-1 endonuclease-dependent retrotranspo-
sitional events causing human genetic disease. Hum Genet 
2005; 117: 411–27.
Experimental Oncology 33, 198–205, 2011 (December) 203
15. Ostertag EM, Goodier JL, Zhang Y, et al. SVA ele-
ments are nonautonomous retrotransposons that cause disease 
in humans. Am J Hum Genet 2003; 73: 1444–51.
16. Batzer MA, Deininger PL. Alu repeats and human 
genomic diversity. Nat Rev Genet 2002; 3: 370–9.
17. Hedges DJ, Batzer MA. From the margins of the 
genome: mobile elements shape primate evolution. Bioassays 
2005, 27: 785–94.
18. Han JS, Boeke JD. LINE-1 retrotransposons: modula-
tors of quantity and quality of mammalian gene expression? 
Bioessays 2005; 27: 775–84.
19. Volff JN. Turning junk into gold: domestication 
of transposable elements and the creation of new genes in euka-
ryotes. Bioessays 2006; 28: 913–22.
20. Miller WJ, Hagemann S, Reiter E, et al. P-element 
homologous sequences are tandemly repeated in the ge-
nome of Drosophila guanche. Proc Nat Acad Sci USA 1992, 
89: 4018–22.
21. Liu D, Bischerour J, Siddique A, et al. The human 
SETMAR protein preserves most of the activities of the an-
cestral Hsmar1 transposase. Mol Cell Biol 2006; 27: 1125–32.
22. Cordaux R, Udit S, Batzer MA, et al. Birth of a chi-
meric primate gene by capture of the transposase gene from 
a mobile element. Proc Natl Acad Sci USA 2006, 103: 8101–6.
23. Lee SH, Oshige M, Durant ST, et al. The SET domain 
protein Metnase mediates foreign DNA integration and links 
integration to nonhomologous end-joining repair. Proc Natl 
Acad Sci USA 2005; 102: 18075–80.
24. Robertson HM, Zumpano KL. Molecular evolution 
of an ancient mariner transposon, Hsmar1, in the human 
genome. Gene 1997, 205: 203–17.
25. Sen SK, Han K, Wang J, et al. Human genomic 
deletions mediated by recombination between Alu elements. 
Am J Hum Genet 2006; 79: 41–53.
26. Kolomietz E, Meyn MS, Pandita A, et al. The role 
of Alu repeat clusters as mediators of recurrent chromosomal 
aberrations in tumors. Genes Chromosomes Cancer 2002; 
35: 97–112.
27. Bailey JA, Liu G, Eichler EE. An Alu transposition 
model for the origin and expansion of human segmental du-
plications. Am J Hum Genet 2003; 73: 823–34.
28. Pidpala OV, Yatsishina AP, Lukash LL. Human mobile 
genetic elements: structure, distribution and functional role. 
Cytol Genetics 2008; 6: 69–81 (in Russian).
29. Feschotte С, Pritham E. DNA transposons and the 
evolution of eukaryotic genomes. Ann Rev Genet 2007; 
41: 331–68. 
30. Quesneville H, Bergman CM, Andrieu O, et al. Com-
bined evidence annotation of transposable elements in genome 
sequences. PLoS Comp Biol 2005; 1: e22. 
31. Miskey C, Izsvak Z, Kawakami K, et al. DNA trans-
posons in vertebrate functional genomics. Cell Mol Life Sci 
2005; 62: 629–41.
32. Capy P, Anxolabehere D, Langin T. The strange phy-
logenies of transposable elements: are horizontal transfers the 
only explanation? TIG 1994; 10: P. 7–12.
33. Callinan PA, Batzer MA. Retrotransposable Elements 
and Human Disease. Genome and Disease. Volff J.N., ed. 
Genome Dyn Basel, Karget, 2006; 1: 104–15.
34. Konkel MK, Batzer MA. A mobile threat to genome 
stability: the impact of non-LTR retrotransposons upon the 
human genome. Sem Cancer Biol 2010; 20: 211–21.
35. Morse B, Rotherg PG, South VJ, et al. Insertional 
mutagenesis of the myc locus by a LINE-1 sequence in a hu-
man breast carcinoma. Nature 1988; 333: 87–90. 
36. Miki Y, Nishisho I, Horii A, et al. Disruption of the 
APC gene by a retrotransposal insertion of L1 sequence 
in a colon cancer. Cancer Res 1992; 52: 643–5.
37. Wallace MR, Andersen LB, Saulino AM, et al. 
A de novo Alu insertion results in neurofibromatosis type 1. 
Nature 1991; 353: 864–6.
38. Jeffs AR, Benjes SM, Smith TL, et al. The BCR gene 
recombines preferentially with Alu elements in complex BCR-
ABL translocations of chronic myeloid leukemia. Hum Mol 
Genetics 1998; 7: 767–76. 
39. Schichman SA, Caligiuri MA, Strout MP, et al. 
ALL-1 tandem duplication in acute myeloid leukemia with 
a normal karyotype involves homologous recombination be-
tween Alu elements. Cancer Res 1994, 54: 4277–80.
40. Onno M, Nakamura T, Hillova J, et al. Rearrangement 
of the human tre oncogene by homologous recombination 
between Alu repeats of nucleotide sequences from two different 
chromosomes. Oncogene 1992; 7: 2519–23.
41. Seisenberger S, Popp  C, Reik W. Retrotransposons 
and germ cells: reproduction, death, and diversity. F1000 Biol 
Rep 2010; 2: 44.
42. Kano H, Godoy I, Courtney C, et al. L1 retrotrans-
position occurs mainly in embryogenesis and creates somatic 
mosaicism. Genes Dev 2009; 23: 1303–12.
43. Lane N, Dean W, Erhardt S, et al. Resistance of IAPs 
to methylation reprogramming may provide a mechanism for 
epigenetic inheritance in the mouse. Genesis 2003; 35: 88–93.
44. Chiu YL, Greene WC. The APOBEC3 cytidine de-
aminases: an innate defensive network opposing exogenous 
retroviruses and endogenous retroelements. Ann Rev Immunol 
2008; 26: 317–53.
45. Nishikura K. Editor meets silencer: crosstalk between 
RNA editing and RNA interference. Nat Rev Mol Cell Biol 
2006; 7: 919–31. 
46. Ono R, Nakamura K, Inoue K, et al. Deletion of Peg10, 
an imprinted gene acquired from a retrotransposon, causes 
early embryonic lethality. Nat Genet 2006; 8: 101–6. 
47. van Gent DC, Mizuuchi K, Gellert M. Similarities 
between initiation of V(D)J recombination and retroviral 
integration. Science 1996; 271: 1592–4.
48. Kapitonov VV, Jurka J. RAG1 core and V(D)J recombi-
nation signal sequences were derived from Transib transposons. 
PLoS Biol 2005; 3: e181. 
49. Reddy YV, Perkins EJ, Ramsden DA. Genomic insta-
bility due to V(D)J recombination-associated transposition. 
Genes Dev 2006; 20: 1575–82. 
50. Jones JM, Gellert M. The taming of a transposon: V(D)
J recombination and the immune system. Immunol Rev 2004; 
200: 233–48.
51. Agrawal A, Eastman QM, Schatz DG. Transposition 
mediated by RAG1 and RAG2 and its implications for the 
evolution of the immune system. Nature 1998; 394: 744–51.
52. Hiom K, Melek M, Gellert M. DNA transposition 
by the RAG1 and RAG2 proteins: a possible source of onco-
genic translocations. Cell 1998; 94: 463–70.
53. Chatterji M, Tsai CL, Schatz DG. Mobilization 
of RAG-generated signal ends by transposition and insertion 
in vivo. Mol Cell Biol 2006; 26: 1558–68.
54. Messier TL, O’Neill JP, Hou SM, et al. In vivo trans-
position mediated by V(D)J recombinase in human T lym-
phocytes. EMBO J 2003; 22: 1381–8.
55. Collier LS, Largaespada DA. Transposable elements 
and the dynamic somatic genome. Genome Biology 2007; 
8: S5.
56. Marculescu R, Vanura K, Montpellier B, et al. 
Recombinase, chromosomal translocations and lymphoid 
204 Experimental Oncology 33, 198–205, 2011 (December)
neoplasia: targeting mistakes and repair failures. DNA Repair 
(Amst) 2006; 5: 1246–58.
57. Lieber MR, Yu K, Raghavan SC. Roles of nonho-
mologous DNA end joining, V(D)J recombination, and class 
switch recombination in in chromosomal translocations. DNA 
Repair (Amst) 2006; 5: 1234–45.
58. Weinstock DM, Richardson CA, Elliott B, et al. Mod-
eling oncogenic translocations: distinct roles for double-strand 
break repair pathways in translocation formation in mamma-
lian cells. DNA Repair (Amst) 2006; 5: 1065–74. 
59. Elliott B, Richardson C, Jasin M. Chromosomal trans-
location mechanisms at intronic alu elements in mammalian 
cells. Mol Cell 2005; 17: 885–94.
60. Weinstock DM, Elliott B, Jasin M. A model of on-
cogenic rearrangements: differences between chromosomal 
translocation mechanisms and simple double-strand break 
repair. Blood 2006; 107: 777–80.
61. Kale SP, Moore L, Deininger PL, et al. Heavy metals 
stimulate human LINE-1 retrotransposition. Int J Environ 
Res Public Health 2005; 2: 14–23.
62. El-Sawy M, Kale SP, Dugan C, et al. Nichel stimulates 
L1 retrotransposition by a post-trancriptional mechanism. 
J Mol Biol 2005; 325: 246–57.
63. Ratner VA, Vasil’eva LA. Mobile genetic elements 
(MGE) and genome evolution. In: Present problems of evo-
lution theory. Tatarinov LP, ed. Мoskow: Nauka 1993: 43–
59 (in Russian).
64. Zabanov SA, Vasil’eva LA, Ratner VA. Induction 
of transposition of MGE Dm412 using gamma-irradiation 
of an isogenic line of Drosophila melanogaster. Genetika 1995; 
31: 798–803 (in Russian).
65. Zakharenko LP, Kovalenko LV, Perepelkina MP, et al. 
The effect of gamma-radiation on induction of the hobo ele-
ment transposition in Drosophila melanogaster. Genetika 2006; 
42: 763–7 (in Russian).
66. Teugels E, De Brakeleer S, Goelen G, et al. De novo 
Alu element targeted to a sequence common to the BRCA1 and 
BCR2 genes. Hum Mutat 2005; 26: 284.
67. El-Sawy M, Deininger P. Tandem insertions of Alu 
elements. Cytogenet Genome Res 2005; 108: 58–62.
68. Kurth R, Bannert N. Beneficial and detrimental ef-
fects of human endogenous retroviruses. Int J Cancer 2010; 
126: 306–14.
69. Gramberg T, Sunseri N, Landau NR. Accessories 
to the crime: recent advances in HIV accessory protein biology. 
Curr HIV/AIDS Rep 2009; 6: 36–42.
70. Lebedev YuB. Endogenous retroviruses: a possible role 
in human cell function. Mol Biol 2000; 34: 544–53 (in Rus-
sian).
71. Grindstaff P, Gruener G. The peripheral nervous 
system complications of HTLV-1 myelopathy (HAM/TSP) 
syndromes. Semin Neurol 2005; 25: 315–27.
72. Roucoux DF, Murphy EL. The epidemiology and dis-
ease outcomes of human T-lymphotropic virus type II. AIDS 
Rev 2004; 6: 144–54.
73. Wainberg MA, Jeang K-T. XMRV as a human patho-
gen? Cell Host & Microbe 2011; 9: 260–2.
74. Kim S, Kim N, Dong B, et al. Integration site prefer-
ence of xenotropic murine leukemia virus-related virus, a new 
human retrovirus associated with prostate cancer. J Virol 2008; 
82: 9964–77.
75. Knouf EC, Metzger MJ, Mitchell PS, et al. Multiple 
integrated copies and high-level production of the human 
retrovirus XMRV from 22Rv1 prostate carcinoma cells. J Virol 
2009; 83: 6995–7003.
76. Preuss T, Fischer N, Boller K, et al. Isolation and char-
acterization of an infection replication-competent molecular 
clone of ecotropic porcine endogenous retrovirus class C. 
J Virol 2006; 80: 10258–61.
77. Tarlinton RE, Meers J, Young PR. Retroviral invasion 
of the koala genome. Nature 2006; 442: 79–81.
78. Mangeney M, Heidmann T. Tumor cells expressing 
a retroviral envelope escape immune rejection in vivo. Proc 
Natl Acad Sci USA 1998; 95: 14920–5. 
79. Blaise S, Mangeney M, Heidmann T. The envelope 
of Mason-Pfizer monkey virus has immunosuppressive proper-
ties. J Gen Virol 2001; 82: 1597–600.
80. Zamudio N, Bourc’his D. Transposable elements in the 
mammalian germline: a comfortable niche or a deadly trap? 
Heredity 2010; 105: 92–104.
81. Howard G, Eiges R, Gaudet F, et al. Activation and 
transposition of endogenous retroviral elements in hypometh-
ylation induced tumors in mice. Oncogene 2008; 27: 404–8. 
82. Slotkin KR, Martienssen R. Transposable elements 
and the epigenetic regulation of the genome. Nature 2007; 
8: 272–85.
83. Wilson AS, Power BE, Molloy PL. DNA hypometh-
ylation and human diseases. Biochim Biophys Acta 2007; 
1775: 138–62.
84. Lu J, Getz G, Miska EA, et al. MicroRNA expression 
profiles classify human cancers. Nature 2005; 435: 834–8.
85. Contreras-Calindo R, Kaplan MH Leissner P., et al. 
Human endogenous retrovirus K (HML-2) element in the 
plasma of people with lymphoma and breast cancer. J Virol 
2008; 82: 9329–36. 
86. Armbruester V, Sauter M, Krautkraemer E, et al. 
A novel gene from the human endogenus retrovirus K ex-
pressed in transformed cells. Clin Cancer Res 2002; 8: 1800–7.
87. Birkmayer GD, Balda BR, Miller F, et al. Virus-like 
particles in metastases of human malignant melanoma. Die 
Naturwissenschaften 1972; 59: 369–70.
88. Serafino A, Balestrieri E, Pierimarchi P, et al. The 
activation of human endogenous retrovirus K (HERV-K) 
is implicated in melanoma cell malignant transformation. Exp 
Cell Res 2009; 315: 849–62.
89. Ashburner M, Golic K, Hawley S. Drosophila A Labo-
ratory Handbook. New York: Cold Spring Harbor Laboratory 
Press, 2004; 311–401.
90. Uren AG, Kool J, Berns A, et al. Retroviral inser-
tional mutagenesis: past, present and future. Oncogene 2005; 
24: 7656–72.
91. Shore SK, Tantravahi RV, Reddy EP. Transforming 
pathways activated by the v-Abl tyrosine kinase.  Oncogene 
2002; 21: 8568–76.
92. Touw IP, Erkeland SJ. Retroviral insertion mutagenesis 
in mice as a comparative oncogenomics tool to identify disease 
genes in human leukemia. Molecular Therapy 2005; 15: 13–9.
93. Kool J, Berns A. High throughput insertional muta-
genesis screens in mice to identify oncogenic networks. Nat 
Rev Cancer 2009; 9: 604.
94. Ivics Z, Izsvak Z. Family of plasmid vectors for the 
expression of beta-galactosidase fusion proteins in eukaryotic 
cells. Biotechniques 1997; 22: 254–8.
95. Ding S, Wu X, Li G, et al. Efficient transposition of the 
piggyBac (PB) transposon in mammalian cells and mice. Cell 
2005; 122: 473–83.
96. Horie K, Yusa K, Yae K, et al. Characterization 
of Sleeping Beauty transposition and its application to genetic 
screening in mice. Mol Cell Biol 2003; 23: 9189–207.
Experimental Oncology 33, 198–205, 2011 (December) 205
97. Shinohara E, Kaminski J, Segal D, et al. Active inte-
gration: New strategies for transgenesis. Transgenic Research 
2007; 16: 333–9.
98. Wu S, Meir Y, Coates C, et al. PiggyBac is a flexible 
and highly active transposon as compared to Sleeping Beauty, 
Tol2, and Mos1 in mammalian cells. Proc Natl Acad Sci USA 
2006; 103: 15008–13.
99. Rad R, Rad L, Wang W, et al. PiggyBac transposon 
mutagenesis: a tool for cancer gene discovery in mice. Science 
2010; 330: 1104–7.
100. Ivics Z, Izsvak Z. The expanding universe of transpo-
son technologies for gene and cell engineering. Mobile DNA 
2010; 1: 25 doi:10.1186/1759–8753–1-25
101. Lavorini-Doyle C, Gebremedhin S, Konopka K, et al. 
Gene delivery to oral cancer cells by nonviral vectors: why some 
cells are resistant to transfection. J Calif Dent Assoc 2009; 
37: 855–8.
102. Touchard E, Kowalczuk L, Bloquel C, et al. The 
ciliary smooth muscle electrotransfer: basic principles and 
potential for sustained intraocular production of therapeutic 
proteins. J Gene Med 2010; 12: 904–19.
103. Casey G, Cashman JP, Morrissey D, et al. Sono-
poration mediated immunogene therapy of solid tumors. 
Ultrasound Med Biol 2010; 36: 430–40.
104. Walther W, Fichtner I, Schlag PM, et al. Nonviral 
jet-injection technology for intratumoral in vivo gene transfer 
of naked DNA. Methods Mol Biol 2009; 542: 195–208.
105. Henikoff S. Conspiracy of silence among repeated 
transgenes. Bioessays 1998; 20: 532–5.
106. Sinn PL, Sauter SL, McCray PB Jr. Gene therapy 
progress and prospects: development of improved lentiviral 
and retroviral vectors–design, biosafety and production. Gene 
Ther 2005; 12: 1089–98.
107. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. 
Insertional oncogenesis in 4 patients after retrovirus-mediated 
gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132–42.
108. Ohlfest JR, Demorest ZL, Motooka Y, et al. Combi-
natorial antiangiogenic gene therapy by nonviral gene transfer 
using the sleeping beauty transposon causes tumor regression 
and improves survival in mice bearing intracranial human 
glioblastoma. Mol Ther 2005; 12: 778–88. 
109. Peng PD, Cohen CJ, Yang S, et al. Efficient nonviral 
Sleeping Beauty transposon based TCR gene transfer to pe-
ripheral blood lymphocytes confers antigen-specific antitumor 
reactivity. Gene Ther 2009; 16: 1042–9. 
110. Izsvak Z, Hackett PB, Cooper LJ, et al. Translating 
Sleeping Beauty transposition into cellular therapies: victories 
and challenges. Bioessays 2010; 32: 756–67.
111. Jin Z, Maiti S, Huls H, et al. Comparative genomic 
integration profiling of Sleeping Beauty transposons mobilized 
with high efficacy from integrase-defective Lentiviral vectors 
in primary human cells. Mol Ther 2011; 19: 1499–510.
112. Belay E, Matrai J, Acosta-Sanchez A, et al. Novel 
hyperactive transposons for genetic modification of induced 
pluripotent and adult stem cells: a nonviral paradigm for coaxed 
differentiation. Stem Cells 2010; 28: 1760–71.
113. Kang Y, Zhang XY, Jiang W, et al. The piggyBac trans-
poson is an integrating non-viral gene transfer vector that en-
hances the efficiency of GDEPT. Cell Biol Int 2009; 33: 509–15. 
114. Grabundzija I, Irgang M, Mates L, et al. Comparative 
analysis of transposable element vector systems in human cells. 
Mol Ther 2010; 18: 1200–9. 
Copyright © Experimental Oncology, 2011
